Volume 4, Issue 2 (Fall & Winter 2020)
J Res Urol 2020, 4(2): 78-86 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Amirzargar M A, Roostaei Hosein Abadi M, Mohsenpour M, Norozi Fard R, Mirtahmasb R. Efficacy of Finasteride in Patients with Bladder Cancer Undergoing Bacillus Calmette-Guérin Therapy. J Res Urol 2020; 4 (2) :78-86
URL: http://urology.umsha.ac.ir/article-1-82-en.html
URL: http://urology.umsha.ac.ir/article-1-82-en.html
Mohamad ali Amirzargar1 
, Mahzad Roostaei Hosein Abadi2 , Mohsen Mohsenpour * 3, Roghayeh Norozi Fard4 , Reyhaneh Mirtahmasb5
, Mahzad Roostaei Hosein Abadi2 , Mohsen Mohsenpour * 3, Roghayeh Norozi Fard4 , Reyhaneh Mirtahmasb5
1- Kidney Transplant Fellowship, Professor, Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
2- Master of Orthopedics and Prosthetics, School of Rehabilitation, Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan Iran
3- Resident of Urology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,mohsenmohsenpur1@yahoo.com
4- Bachelor of Physiology, Hamadan University of Medical Sciences, Hamadan, Iran
5- Resident of Neurology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2- Master of Orthopedics and Prosthetics, School of Rehabilitation, Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan Iran
3- Resident of Urology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,
4- Bachelor of Physiology, Hamadan University of Medical Sciences, Hamadan, Iran
5- Resident of Neurology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract: (3759 Views)
Background and Objective: Despite the widespread use of Bacillus Calmette-Guérin (BCG) for the treatment of superficial bladder tumors, recurrence and treatment failure is common among a significant proportion of patients..In this regard the addition of finasteride to BCG treatment may increase the effectiveness of bladder cancer treatment. The present study aimed to assess the effectiveness of finasteride in patients with bladder cancer undergoing BCG therapy
Materials and Methods: In this retrospective cohort study, 70 men with bladder cancer who were treated with BCG alone (control group, n=35) and BCG with finasteride (case group, n=35) in Shahid Beheshti Hospital in Hamadan from 2018 to 2019 were compared in terms of treatment efficacy. Data were analyzed by SPSS software (version 21) at a 95% confidence interval.
Results: The mean duration of follow-up was 2.29±1.55 years; moreover,, the mean age scores of patients in the case and control groups were reported as 66.00±8.95 and 62.94 ±13.69 years, respectively (P=0.273). The frequency rates of recurrence of bladder cancer in patients receiving BCG with finasteride and BCG alone were obtained at 17.1% and 31.4%, respectively (P=0.163). The mean recurrence times were as 8.50 and 7.27 months in the case and control groups, respectively (P=0.404).
Conclusion: As evidenced by the obtained results in patients with bladder cancer, the addition of
finasteride tablets to the BCG treatment regimen reduces the frequency and effectiveness of the disease.
Materials and Methods: In this retrospective cohort study, 70 men with bladder cancer who were treated with BCG alone (control group, n=35) and BCG with finasteride (case group, n=35) in Shahid Beheshti Hospital in Hamadan from 2018 to 2019 were compared in terms of treatment efficacy. Data were analyzed by SPSS software (version 21) at a 95% confidence interval.
Results: The mean duration of follow-up was 2.29±1.55 years; moreover,
Conclusion: As evidenced by the obtained results in patients with bladder cancer, the addition of
finasteride tablets to the BCG treatment regimen reduces the frequency and effectiveness of the disease.
Type of Study: Research |
Subject:
Urologic oncology
Received: 2021/07/27 | Accepted: 2021/08/23 | Published: 2021/09/3
Received: 2021/07/27 | Accepted: 2021/08/23 | Published: 2021/09/3
References
1. Mazdak H, Tolou GZ, Gholumpour M. Investigation of bladder cancer incidence in Isfahan, Iran. Tehran Univ. Med. J. 2019;77(4):252-6.
2. Goonewardene SS, Persad R, Motiwala H, Albala D. Systematic Review Results on Bladder Cancer Epidemiology, Occupational Hazards and Risk Factors. Management of Non-Muscle Invasive Bladder Cancer. 2020:53-61.
3. Jahrreiss V, Pradere B, Laukhtina E, Mori K, Shariat SF. Catalog of exogenous risk factors for bladder carcinogenesis. Curr. Opin. Urol . 2020;30(3):449-56.
4. Li F, Hong X, Hou L, Lin F, Chen P, Pang S, Du Y, Huang H, Tan W. A greater number of dissected lymph nodes is associated with more favorable outcomes in bladder cancer treated by radical cystectomy: a meta-analysis. Oncotarget. 2016;7(38):61284. [DOI:10.18632/oncotarget.11343]
5. DeGEORGE KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. Am Fam Physician. 2017;96(8):507-14.
6. Guallar-Garrido S, Julián E. Bacillus Calmette-Guérin (BCG) therapy for bladder cancer: an update. ImmunoTargets Ther. 2020;9:1. [DOI:10.2147/ITT.S202006]
7. Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed. Pharmacother. 2020;129:110393. [DOI:10.1016/j.biopha.2020.110393]
8. Li P, Chen J, Miyamoto H. Androgen receptor signaling in bladder cancer. Cancers. 2017;9(2):20. [DOI:10.3390/cancers9020020]
9. Mizushima T, Tirador KA, Miyamoto H. Androgen receptor activation: a prospective therapeutic target for bladder cancer? Expert Opin. Ther. Targets. 2017; 21(3):249-57.
10. Luna‐Velez MV, Dijkstra JJ, Heuschkel MA, Smit FP, van de Zande G, Smeets D, Sedelaar JM, Vermeulen M, Verhaegh GW, Schalken JA. Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder. Molecular Oncology. 2021.
11. van Puffelen JH, Keating ST, Oosterwijk E, van der Heijden AG, Netea MG, Joosten LA, Vermeulen SH. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nature Reviews Urology. 2020;17(9):513-25. [DOI:10.1038/s41585-020-0346-4]
12. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BW, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update. European urology. 2019;76(5):639-57. [DOI:10.1016/j.eururo.2019.08.016]
13. Larsen ES, Joensen UN, Poulsen AM, Goletti D, Johansen IS. Bacillus Calmette-Guerin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. Apmis. 2020 Feb;128(2):92-103.
14. Koch GE, Smelser WW, Chang SS. Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How to Manage Them. Urology. 2020.
15. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. The Journal of urology. 2003 Jan;169(1):96-100.
16. Williams SB, Howard LE, Foster ML, Klaassen Z, Sieluk J, De Hoedt AM, Freedland SJ. Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System. JAMA network open. 2021 Mar 1;4(3):e213800-.
17. Juvet, T., Mari, A., Lajkosz, K., Wallis, C.J., Kuk, C., Erlich, A., Krimus, L., Fleshner, N.E., Kulkarni, G.S. and Zlotta, A.R., 2020, November. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. In Urologic Oncology: Seminars and Original Investigations (Vol. 38, No. 11, pp. 850-e9). Elsevier.
18. Zhu D, Srivastava A, Agalliu I, Fram E, Kovac EZ, Aboumohamed A, et al. Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population. The Journal of Urology. 2021
http://doi.org/10.1097/JU.0000000000001694
19. Morales EE, Grill S, Svatek RS, Kaushik D, Thompson Jr IM, Ankerst DP, Liss MA. Finasteride reduces risk of bladder cancer in a large prospective screening study. European urology. 2016; 69(3):407-10. [DOI:10.1016/j.eururo.2006.07.001]
20. Moroz A, Delella FK, Almeida R, Lacorte LM, Favaro WJ, Deffune E, Felisbino SL. Finasteride inhibits human prostate cancer cell invasion through MMP2 and MMP9 downregulation. PLoS One. 2013;8(12):e84757.
21. Mäkelä VJ, Kotsar A, Tammela TL, Murtola TJ. Bladder cancer survival of men receiving 5α-reductase inhibitors. The Journal of urology. 2018;200(4):743-8. [DOI:10.1016/j.juro.2018.04.082]
22. Yong C, Steinberg RL, O'Donnell MA. Severe infectious complications of intravesical Bacillus Calmette-Guérin: a case series of 10 patients. Urology. 2020 137:79-83.
23. Liu L, Zhao S, Li F, Li E, Kang R, Luo L, Luo J, Wan S, Zhao Z. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. The journal of sexual medicine. 2016;13(9):1297-310. [DOI:10.1016/j.jsxm.2016.07.006]
24. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α‐reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. The journal of sexual medicine. 2011;8(3):872-84. [DOI:10.1111/j.1743-6109.2010.02157.x]
25. Kakehi Y, Hirao Y, Kim WJ, Ozono S, Masumori N, Miyanaga N, Nasu Y, Yokomizo A. Bladder cancer working group report. Japanese journal of clinical oncology. 2010;40(suppl_1):i57-64.
26. Fankhauser CD, Mostafid H. Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle. Current opinion in urology. 2018;28(1):88-92. [DOI:10.1097/MOU.0000000000000452]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences.
Published by UMSHA Press
Journal Tel: +9881 38380283
Publisher Tel: +988138380548
Website: http://urology.umsha.ac.ir
Email: urology [at]umsha.ac.ir
